Individualizing therapy for neovascular age-related macular degeneration with aflibercept
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2016
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms VITAL
- 11 Jul 2016 Last checked against ClinicalTrials.gov record.
- 06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2016 Accrual to date is 96% according to United Kingdom Clinical Research Network record.